Your session is about to expire
← Back to Search
Inotuzumab Ozogamicin for B-Cell Lymphoma
Study Summary
This trial is testing a new cancer treatment combining a monoclonal antibody with chemotherapy to see if it's more effective than chemo alone at treating patients with B-cell acute lymphoblastic leukemia that has come back or stopped responding to treatment.
- B Acute Lymphoblastic Leukemia
- B Lymphoblastic Lymphoma
- B-Cell Lymphoma
- Acute Lymphoblastic Leukemia
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 trial • 72 Patients • NCT01363297Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How does this research compare to prior experiments of its genre?
"Inotuzumab Ozogamicin has been subject to scientific inquiry since 1997, when Alfacell sponsored a study involving 300 participants. After passing Phase 3 drug approval trials, the medication is currently being researched in 1440 different clinical studies across 81 nations and 3003 cities worldwide."
Has Inotuzumab Ozogamicin obtained regulatory approval from the FDA?
"We rate the safety of Inotuzumab Ozogamicin a 1, as this is an early-phase trial with limited evidence on both efficacy and safety."
What ailments commonly benefit from the application of Inotuzumab Ozogamicin?
"Inotuzumab Ozogamicin can be utilized as a form of therapy for prostate cancer, pheochromocytomas, and ulcerative colitis."
Could you elucidate on any other research conducted regarding Inotuzumab Ozogamicin?
"Currently, 1440 clinical trials are dedicated to Inotuzumab Ozogamicin with 322 of those studies having advanced into Phase 3. These research sites have been dispersed across 54 469 locations and the majority can be found in Bethesda, Maryland."
Is this clinical investigation currently accepting participants?
"This particular study has ceased participant recruitment. It was posted on September 24th 2019 and last updated on the 21st of September 2022. If one is in search of other trials, there are 3727 clinical studies for lymphoma patients currently recruiting and 1440 for Inotuzumab Ozogamicin specifically accepting participants."
What is the current cohort size of this experiment?
"Unfortunately, this clinical trial is currently not accepting participants at present. The initial posting was on September 24th 2019 and the last edit occured on September 21st 2022. However, there are 3727 trials for lymphoma active enrollment and 1440 studies recruiting patients with Inotuzumab Ozogamicin respectively."
Share this study with friends
Copy Link
Messenger